您现在的位置: 首页> 研究主题> B7-1

B7-1

B7-1的相关文献在1997年到2022年内共计112篇,主要集中在肿瘤学、基础医学、分子生物学 等领域,其中期刊论文109篇、会议论文2篇、专利文献1篇;相关期刊78种,包括中国学术期刊文摘、中国免疫学杂志、中国实验血液学杂志等; 相关会议1种,包括黑龙江省免疫学会成立十周年学术会议等;B7-1的相关文献由415位作者贡献,包括邱玉华、刘影、张文真等。

B7-1—发文量

期刊论文>

论文:109 占比:97.32%

会议论文>

论文:2 占比:1.79%

专利文献>

论文:1 占比:0.89%

总计:112篇

B7-1—发文趋势图

B7-1

-研究学者

  • 邱玉华
  • 刘影
  • 张文真
  • 司履生
  • 王一理
  • 刘岩
  • 沈立军
  • 王志华
  • 刘树铮
  • 刘然义
  • 期刊论文
  • 会议论文
  • 专利文献

搜索

排序:

年份

期刊

    • 沈立军; 朱雪梅; 邱玉华(指导)
    • 摘要: 目的:研究鼠抗人单克隆抗体B7-1对恶性肿瘤细胞株Daudi(天然表达B7-1分子)体外生长、蛋白表达谱及信号通路的影响。方法:①采用诱生腹水法制备小鼠抗人B7-1单克隆抗体(4E5 mAb),应用Protein A免疫层析法进行亲和纯化,流式细胞术对其纯化后产物的活性进行识别鉴定;②利用MTT法检测不同浓度的4E5 mAb(5、10、20、40μg/ml)对Daudi细胞体外增殖的影响;③应用Label-free蛋白定量技术分析比较4E5 mAb(20μg/ml)处理Daudi细胞48 h后与其对照组(同型对照IgG)蛋白质的差异表达情况,采用平行反应监测(PRM)对差异表达蛋白进行定量验证;④根据蛋白质的GO注释和生物信息学工具KEGG数据库将鉴定出来的差异蛋白质进行生物信息学富集分析。结果:①获得单克隆抗体的量为3.83 mg/ml,该抗体与Daudi肿瘤细胞的阳性结合率为93.7%;②当抗体终浓度为20μg/ml时,4E5 mAb显著抑制Daudi细胞的增殖;③与IgG对照组相比,4E5实验组鉴别出169个蛋白质的定量水平差异有统计学意义,其中131个蛋白质表达呈上调趋势,38个蛋白表达水平呈下调趋势,PRM对差异蛋白定量验证的结果与蛋白组学结果完全一致;④GO数据库分析的差异表达蛋白主要来自线粒体、内质网膜、高尔基体、核质等细胞器,其中又以线粒体附近分布最多,多数参与线粒体翻译延伸和终止、细胞增殖、mRNA剪接、翻译、细胞内蛋白运输等功能。生物信息学工具KEGG富集分析显示差异蛋白主要参与Daudi细胞增殖相关的通路,如PI3KAkt、Ras、DNA replication、AMPK、mTOR、Hippo、VEGF、FoxO、Metabolic等。结论:小鼠抗人B7-1 mAb不仅可以通过与肿瘤细胞膜表面的B7-1分子特异性结合进行相互作用,还能显著抑制天然表达B7-1分子的肿瘤细胞的增殖,且与B7-1 mAb结合后明显改变了肿瘤细胞中蛋白表达谱及与增殖相关的信号通路。
    • 摘要: 近日,国家药品监督管理局通过优先审评审批程序附条件批准康方药业有限公司卡度尼利单抗注射液(商品名:开坦尼)上市。该药品为我国自主研发的创新双特异性抗体,适用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患者的治疗。卡度尼利单抗注射液是一种靶向人PD-1和CTLA-4的双特异性抗体,可阻断PD-1和CTLA-4与其配体PD-L1/PD-L2和B7.1/B7.2的相互作用,从而阻断PD-1和CTLA-4信号通路的免疫抑制反应,促进肿瘤特异性的T细胞免疫活化,进而发挥抗肿瘤作用。
    • 茅燕萍; 王亿平; 陈成; 张磊; 魏玲; 任克军; 金华; 王东; 章雪莲
    • 摘要: [目的]观察参地颗粒对于脾肾亏虚型慢性肾小球肾炎(CGN)患者外周细胞毒T淋巴细胞相关抗原-4(CTLA-4)、外周单个核细胞B7-1(CD80)水平和血清白细胞介素2(IL-2)、白细胞介素6(IL-6)、干扰素γ(IFN-γ)的影响,探讨参地颗粒对CGN患者的CTLA-4/B7-1介导的免疫炎症紊乱的干预作用.[方法]将60例脾肾亏虚型CGN患者随机分为治疗组和对照组,每组各30例;另选择20例同期健康体检者作为正常组.2组患者均给予西医常规治疗,治疗组同时给予参地颗粒治疗,对照组同时给予缬沙坦胶囊治疗,疗程12周.观察2组治疗前后24 h尿蛋白定量(24hUPr),外周血B7-1、IL-2、IL-6、IFN-γ及尿B7-1水平的变化情况,并评价2组的疗效.[结果](1)治疗组剔除2例,对照组剔除3例,最终治疗组28例、对照组27例完成试验.(2)治疗后,2组患者的中医证候积分均较治疗前下降(P0.05);治疗组在治疗8周、12周后的24hUPr含量均较治疗前明显降低(P0.05).[结论]CGN患者体内CTLA-4/B7-1信号系统存在紊乱,引起Th1/Th2细胞失衡,造成炎症因子的分泌和免疫复合物的沉积,导致系膜增生、系膜基质增多,肾小球损害加重.参地颗粒可以减少24hUPr,调节慢性肾小球肾炎患者共刺激信号系统,下调IFN-γ、IL-6等细胞炎症因子,平衡Th1/Th2细胞,抑制免疫紊乱的继续,减轻肾脏病理损害.
    • 程金波; 熊加川
    • 摘要: 作为肾小球滤过屏障主要组成部分的足细胞,在特定致炎因素诱导下,可具有抗原呈递的特性,扮演非专职抗原呈递细胞的角色,并启动自身免疫反应,从而导致足细胞损伤和蛋白尿,可能在糖尿病肾病、狼疮性肾炎、微小病变肾病、局灶节段性肾小球硬化及膜性肾病等肾小球足细胞疾病的发病中起作用.因此,阻断由足细胞启动的抗原呈递过程,有望为治疗此类疾病的新的途径.近年来,抗原呈递阻断剂CTLA4-Ig融合蛋白制剂在肾小球疾病的临床实践证实了这种可能,本文就肾脏足细胞B7-1抗原呈递与CTLA4-Ig的研究进展作一综述.
    • 贾评评; 宋丹; 宋纯东; 陈瑶; 花淑婷
    • 摘要: 目的:观察张仲景治疗水肿经方真武汤、越婢加术汤对阿霉素肾病模型大鼠肾组织B7-1表达的影响,探讨两种不同利水法疗效及中医"同病异治"分子机制。方法:雄性SD大鼠48只随机分为空白组、模型组、真武组及越婢组。采用尾静脉注射阿霉素建立肾病模型,分别灌胃相应药物。6周后检测各组大鼠24小时尿蛋白定量,肝功能:血清白蛋白(albumin,ALB)、谷丙转氨酶(alanine transaminase,ALT),肾功能:血肌酐(serum creatinine,Scr)、血尿素氮(urea nitrogen,BUN)及血脂:胆固醇(cholesterol,CHOL)、三酰甘油(triacylglycerol,TG)。HE染色观察大鼠肾脏病理;免疫组织化学法检测肾组织B7-1表达。结果:与模型组24小时尿蛋白定量[(0.40±0.82)g]比较,真武组[(0.18±0.88)g]和越婢组[(0.20±0.76)g]均降低(P<0.05);与模型组ALB[(12.30±1.74) g·L^-1]比较,真武组[(18.82 ±2.19)g·L^-1]和越婢组[(20.33±4.90)g·L^-1]均升高(P<0.05);与模型组Scr[(80.00±39.96)mmol·L-1]比较,真武组[(67.67±44.86)mmol·L^-1]和越婢组[(60.83±31.30)mmol·L^-1]均降低(P<0.05);与模型组血脂(CHOL、TG)比较,真武组和越婢组均下降(P<0.05)。肾脏病理:模型组可见部分肾小球肥大、少数系膜增生和肾小管病变,而真武组和越婢组改变均较轻微。与模型组B7-1水平[(79.37±4.24])比较,真武组[(56.82±5.52)]和越婢组[(52.38±3.61)]表达水平均较低(P<0.05)。结论:真武汤和越婢加术汤可能通过影响阿霉素肾病模型大鼠肾组织B7-1的表达,调节免疫而改善肝功能、肾功能,减轻肾脏病理损害。
    • 韩莲花; 沈立军; 朱莹; 邱玉华
    • 摘要: 目的 探讨B7-1、B7-2单克隆抗体分别通过阻断或削弱B7/CD28协同刺激分子信号通路对SLE小鼠模型的免疫干预效应以及可能的分子机制.方法 C57BL/J6×BALB/c杂交F1代小鼠,取60只雌性F1代小鼠分成4组:正常对照组,模型组,B7-1干预组,B7-2干预组.B7-1干预组在淋巴细胞注射完后的第1、3、5、8、15、30、60天,通过尾静脉分别注射B7-1单抗(克隆4E5),每只小鼠注射抗体量为8 mg/kg,B7-2干预组在相同时间给予B7-2单抗(克隆1D1),模型组相同时间给予等剂量的小鼠Ig同型对照.分析自身抗体、尿蛋白、免疫复合物和肾脏组织改变情况等指标.结果 模型组小鼠第2周就能检测到dsDNA的表达,4周能检测到ANA的表达.B7-1干预组、B7-2干预组能检测到dsDNA和ANA的时间晚于模型组,而且抗体滴度都低于模型组.第12周,模型组小鼠均出现蛋白尿.B7-1干预组和B7-2干预组分别有50%、40%的小鼠出现蛋白尿,蛋白量低于模型组.模型组小鼠肾脏组织HE染色可见肾小球组织病理病变明显,结构紊乱,免疫荧光染色显示肾小球部位可见颗粒状或线性的荧光.电子显微镜扫描可见肾小球脏层上皮细胞和基底膜之间存在大量电子致密物,基底膜节段性增厚.B7-1干预组、B7-2干预组肾小球病理改变较轻,肾小球部位可见少量荧光,肾小球脏层上皮细胞和基底膜之间可见少量电子致密物,基底膜厚度也没有明显增厚.结论 B7-1、B7-2单抗干预都能阻断或削弱B7/CD28共刺激信号通路,减少自身抗体的生成,从而能减轻免疫复合物对狼疮小鼠肾功能的损伤.B7-2单抗能更特异性地减少自身抗体的产生,因此对SLE小鼠肾炎的发生发展有更好的延缓作用.提示阻断协同刺激分子的方法有望为SLE等自身免疫性疾病提供高效低毒的生物疗法.
    • 杜爱民; 陈星华; 杨倩; 颜奇; 梁伟; 丁国华
    • 摘要: Objective To observe the effect of costimulatory molecule B7-1 on cytoskeleton rearrangement in mouse podocytes induced by angiotensin Ⅱ (Ang Ⅱ),and to study the underlying molecular mechanism of B7-1 in the pathological changes of podocytes.Methods All cultivation of conditionally immortalized mouse podocytes (MPC) in vitro were divided into the following groups:normal control group,CTLA-4 group,Ang Ⅱ group (10-6 mmol/L 12 h,24 h;10-8 mmol/L 12 h,24 h) and CTLA-4 with Ang Ⅱ group.Transfect B7-1 RNA interference fragment (siRNA) to the mature podocytes,and then restimulated by Ang Ⅱ (10-6 mmol/L 12 h),the change of podocyte cytoskeleton after Ang Ⅱ stimulation were observed.The expression of B7-1 in each group was assayed by flow cytometry and Western blotting.The nephrin and p-nephrin protein levels in the four groups were also analyzed by Western blotting.At the same time,the podocyte cytoskeleton distribution as indicated by F-actin was observed by fluorescence microscopy.Results Flow cytometry and Western blotting showed that B7-1 was not expressed in the normal control group.Ang Ⅱ showed a concentration and time dependent induction of B7-1 expression in mouse podocytes (P < 0.05).Western blotting indicated that Ang Ⅱ induced B7-1 protein expression (P < 0.05).Expression of nephrin and p-nephrin was significantly down-regulated by Ang Ⅱ (P < 0.05).Compared with the normal control group,the expression of podocyte protein nephrin and p-nephrin in Ang Ⅱ stimulation group was significantly reduced (P < 0.05).Using FITC phalloidin fluorescence staining showed that CTLA-4+Ang Ⅱ stimulation group cytoskeleton rearrangement was improved significantly and F-actin recombinant score (mCFS) decreased compared with Ang Ⅱ group (P < 0.05),suggesting that Ang Ⅱ led to the disorder of the podocytes cytoskeleton and the destruction of the cytoskeleton of podocytes by Ang Ⅱ could be improved after B7-1 blocking.Compared with the Ang Ⅱ stimulation,transfection of B7-1 siRNA + Ang Ⅱ stimulation group improved F-actin cytoskeletal rearrangement,and mCFS also decreased significantly (P < 0.05),suggesting that transfection of B7-1 siRNA might improve the damage of Ang Ⅱ on podocytes cytoskeleton.Conclusions B7-1 participates in the process of cytoskeleton reconstruction and plays an important role in the pathological changes of podocytes.%目的 观察共刺激分子B7-1对血管紧张素Ⅱ(AngⅡ)诱导的小鼠足细胞骨架重排的影响,探讨B7-1在足细胞病变中的作用以及可能的分子机制.方法 体外培养条件永生性小鼠足细胞(MPC),分组如下:正常对照组、AngⅡ刺激组、CTLA-4(B7-1封闭剂)干预组和CTLA-4干预+AngⅡ刺激组.转染B7-1 RNA干扰片段(siRNA)至分化成熟的足细胞,再予10-6 mmol/L AngⅡ刺激12h,观察沉默B7-1基因对AngⅡ刺激下足细胞骨架改变的影响.用流式细胞术检测足细胞B7-1表达;Western印迹法检测足细胞B7-1、nephrin、p-nephrin分子的表达;异硫氰酸荧光素(FITC)-鬼笔环肽荧光染色法观察足细胞骨架蛋白F-actin表达.结果 流式细胞术和Western印迹结果显示,正常对照组足细胞B7-1无表达,AngⅡ刺激组足细胞B7-1表达明显增加,且随AngⅡ刺激浓度增加和时间延长B7-1表达增加(均P<0.05).与正常对照组比较,AngⅡ刺激组足细胞nephrin和p-nephrin表达量明显下调(均P<0.05).FITC-鬼笔环肽荧光染色结果显示,与AngⅡ刺激组比较,CTLA-4干预+AngⅡ刺激组细胞骨架重排改善,F-actin重组评分(mCFS)明显降低(P<0.05),提示封闭B7-1可改善AngⅡ对足细胞细胞骨架的破坏;与AngⅡ刺激组比较,转染B7-1 siRNA+AngⅡ刺激组细胞骨架重排改善,F-actin mCFS亦明显降低(P<0.05),提示转染B7-1 siRNA亦可改善AngⅡ对足细胞细胞骨架的破坏.结论 B7-1参与足细胞骨架重排过程,在足细胞损伤中起重要作用.
    • 郝晓东; 李常颖; 薄志强; 丁浩; 张昌文; 张志宏
    • 摘要: Objective:To construct the fusion vaccine with dendritic cells and prostate cancer cells (PC3) and modify it by B7.1/GM-CSF,and test the anti-tumor immunological reaction of the fusion vaccine in vitro.Methods:Fusion cells was electrofusioned by DC and GM-CSF-PC3,and B7.1/GPI protein was constructed and anchored to the fusion cell surface;Cell morphology and anchoring stability were determined by immunofluorescence,and fusion cell phenotype were determined by flow cytometry;fusion vaccines stimulated homologous proliferation and cytotoxic effect of allogeneic T lymphocytes were determined by MTT and LDH kit.Results:B7.1/GM-CSF fusion vaccine highly expressed DC molecular markers and prostate cancer markers;B7.1/GM-CSF fusion vaccines strongly promoted the proliferation of T cells and induced a significantly tumor-specific cytotoxic T lymphocyte (CTL) response and killed the PC3 cells effectively in vitro.Conclusion:The DC and GM-CSF-PC3 can be successfully fused by electrical fusion technique,and the specific modified fusion vaccine can significantly enhance the anti-tumor immune effect in vitro.%目的:制作B7.1/GM-CSF修饰的DC融合疫苗,并观察其在体外的特异性抗肿瘤免疫效应.方法:制备完整表达GM-CSF的前列腺癌细胞(PC3细胞),从前列腺癌患者外周血中分离树实状细胞(DC),应用电融合法融合DC和GM-CSF-PC3,构建B7.1/GPI蛋白并锚定于融合细胞表面;应用免疫荧光观察融合细胞形态及锚定稳定性;流式细胞进行融合细胞表形测定;ELISA试剂盒检测IFN-γ分泌情况;MTr及LDH试剂盒测定融合细胞刺激同源异体T淋巴细胞增殖和细胞毒性效应.结果:成功制备GM-CSF-PC3细胞及B7.1/GPI蛋白,成功分离DC并表达DC分子标记;B7.1/GM-CSF融合疫苗高表达DC分子标记及前列腺癌标记;T细胞增殖实验证明融合疫苗具有强烈的免疫刺激活性;细胞毒性实验证明了融合细胞具有比对照组更有效的肿瘤杀伤作用.结论:电融合技术可成功诱导DC与GM-CSF-PC3融合,体外实验中特定修饰的融合疫苗可显著的提升抗肿瘤免疫效应.
    • 孔永; 沈立军; 王婧; 朱莹; 蔡磊; 邱玉华; 黄莉
    • 摘要: Objective:To construct lentiviral vector specific for mouse B7-1 RNA interference and study lentivirus-mediated B7-1 gene silencing effects in L929 fibroblast cells.Methods:Three candidate sequences for B7-1 RNAi selected from coding sequence of mouse B7-1 transcription were used to design short hairpin RNA ( shRNA ) templates and then cloned into lentiviral expression plasmid followed with correctness identification of inserted sequence by DNA sequencing.Recombinant lentivirus were prepared by co-transfecting lentiviral expression vector and packaging plasmids into 293T cells.Then the resulting culture supernatant containing infectious lentiviral particles was pooled and centrifuged via ultra-centrifugation.Infectious titer of the preparations was determined by detecting the expression of GFP in 293T cells after transfected by lentivirus.Cultured L929 cells were transfected with lentivirus to deter-mine transduction efficiency and silencing efficacy of B7-1 expression by flow cytometry.Transducted L929 cells were then screened using puromycin to generate stable cell clones followed by flow cytometry analysis of GFP and B7-1 expression.A mixed reaction system consisting of stable B7-1 silencing L929 cells and mouse splenic T cells was used to analyze ability of the established cell line to trigger T cells proliferation.Results: Lentiviral expression vector for mouse B7-1 RNAi was correctly constructed with inserted sequences as designed.Recombinant RNAi lentivirus were prepared with titers ranging (3-5) ×108 TU/ml and efficacy to mediate GFP transgene expression and B7-1 silencing.B7-1 expression and the ability to trigger T cells proliferation of stable L929 cells were suppressed significantly ( P<0.05 ).Conclusion: We generated lentiviral vector specific for mouse B7-1 RNAi with high performance of transduction efficiency as well as B7-1 silencing efficacy and the recombinant RNAi lentivirus can mediated stable B7-1 gene silencing in L929 cells and inhibition of T cells proliferation induced by B7-1/CD28 co-stimulatory signal.%目的:构建介导小鼠B7-1基因RNAi的慢病毒载体,研究其对L929细胞表面B7-1分子表达的沉默效应。方法:从小鼠B7-1基因编码区选择3段RNA干扰靶序列,制备转录双发夹RNA的前体DNA,并克隆至慢病毒穿梭质粒,构建B7-1的RNAi慢病毒穿梭载体,测序鉴定。将重组质粒及辅助质粒共转染293T细胞产生慢病毒,经超速离心获得浓缩慢病毒颗粒。通过测定293T细胞GFP表达水平确定病毒滴度,流式细胞术检测感染效率以及对细胞表面B7-1的干扰效率。病毒感染细胞经嘌呤霉素筛选及克隆培养获得小鼠B7-1基因RNAi慢病毒稳定感染的L929细胞,流式细胞术分析细胞中GFP及B7-1分子表达的状况;将感染细胞与分离的小鼠脾脏T细胞混合培养,分析B7-1稳定沉默细胞刺激T细胞增殖的能力。结果:成功了构建小鼠B7-1基因RNA干扰的重组慢病毒载体;获得了滴度达(3~5)×108 TU/ml的浓缩重组慢病毒,重组慢病毒可有效感染L929细胞介导GFP表达以及沉默其表面的B7-1。经筛选获得慢病毒稳定感染的L929细胞,该细胞表面B7-1分子表达受到抑制,刺激T细胞增殖的能力显著下降(P<0.05)。结论:构建了能够高效感染及沉默小鼠B7-1分子的RNAi慢病毒载体,该载体可稳定沉默L929细胞表面B7-1分子表达,抑制B7-1/CD28信号诱导的T细胞增殖效应。
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号